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Abstract
Inflammatory diseases (bronchitis, irritable bowel diseases, psoriasis, chronic 
obstructive pulmonary disease, rheumatoid arthritis, conjunctivitis, hepatitis, 
rhinitis, etc.) are increasingly becoming the cause of health concern across the 
world. For both developed and developing countries, the public health cost attached 
to the management of these complications is increasing each year. Control of diet 
is one of the critical strategies to improve the therapeutic potentials of clinically 
proven drugs. Among the dietary factors, bioactive lipids, particularly polyun-
saturated fatty acids, elicit essential effects of modulating signaling pathways that 
could provide a beneficial effect in individuals suffering from various inflammatory 
complications. Among the polyunsaturated fatty acids, both n-3 and n-6 fatty acids 
exhibit differential effects, and their dietary ratio plays a significant role in the 
overall impact in an individual. This is most evident with the fact that the decrease 
in the n-3 intake in recent times has significantly contributed to the severity of 
chronic inflammation. The mechanism by which these fatty acids and bioactive 
unsaponifiable embedded in the dietary oils modulate the critical genes, thereby 
alter the pathology of inflammatory complications is under study for many decades. 
In this chapter, the role of polyunsaturated fatty acids and their modulatory effects 
on some of the significant inflammatory complications are discussed.
Keywords: arthritis, chronic obstructive pulmonary disease, inflammation,  
irritable bowel diseases, polyunsaturated fatty acids, psoriasis
1. Introduction
Inflammation is a natural phenomenon for healing that occurs through the 
body’s immune response. The cellular reactions remove the threat that may be in 
the form of a pathogen, damaged cell, irritant, and other foreign particles. Often, 
they are self-limiting; however, under certain circumstances, they can cause 
permanent damages to healthy tissues and eventually to the entire organ system. 
The phenomenon of inflammation is caused by specific lipid-derived and small 
molecular weight proteins referred to as eicosanoids and cytokines, respectively. 
The cellular and systemic level of eicosanoids and cytokines, and the relative 
presence of pro- vs. anti-inflammatory mediators determines overall inflamma-
tory milieu in an individual. Uncontrolled and chronic inflammation triggers 
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many common conditions and diseases. Bronchitis, conjunctivitis, chronic 
obstructive pulmonary disease (COPD), hepatitis, irritable bowel disease (IBD), 
psoriasis, rheumatoid arthritis (RA), and rhinitis are known to have a critical 
link with eicosanoids productions that eventually leads inflammation [1–8]. Even 
though effective pharmaceutical interventions are available to treat as well as 
manage these complications, adjunct therapies involving dietary management 
is mostly recommended [9, 10]. Nutraceutical intervention in the management 
of these inflammatory complications is gaining importance due to convenience, 
safety, and the low-cost attached in it Investigations have pointed out that n-3 
polyunsaturated fatty acids (n-3 PUFA) positively alter inflammatory pathways. 
Their actions aid in reduced levels of eicosanoids (20 carbon lipid-derived 
molecules) and other inflammatory biomarkers, such as interleukin-1b (IL-1b), 
IL-6, and tumor necrosis factor-α (TNF- α) in plasma and urine, by serving as 
secondary messengers or modifying the transcriptional regulation of particular 
genes involved in inflammation [11]. In contrast, a high intake of dietary n-6 
polyunsaturated fatty acids (n-6 PUFA) is associated with increased synthesis 
of proinflammatory eicosanoids synthesized from arachidonic acid metabolism, 
which include leukotrienes, lipoxins, thromboxanes, prostaglandins, and hydroxy 
fatty acids, and suppresses the synthesis of anti-inflammatory eicosanoids 
derived from EPA and DHA [12].
The modern (mostly western) diet is a poor source of n-3 PUFA, with an abys-
mal n-3:n-6 fatty acid ratio of 1:15–20, which is in sharp contrast to that found in 
the diet followed by our ancestors-1:1 [13, 14]. Both n-3 and n-6 PUFA consumed in 
the diet compete for the same enzymes and also regulate many transcription factors 
which impact cellular and tissue metabolism, and, a skewed ratio of n-3:n-6 PUFA 
result in the altered equilibrium in composition and fluidity of cell membrane as 
well as the functionality of organs [15, 16]. Evidence is accumulating that these 
physiological changes have led to interactions between constituents of the diet and 
genes, culminating in the rise of local and systemic inflammation. It is coupled with 
the disruption of immune/defense mechanism leading to rheumatoid arthritis, 
chronic obstructive pulmonary disease, irritable bowel diseases, psoriasis, bronchi-
tis, rhinitis, hepatitis, conjunctivitis, etc.
2.  Therapeutic potential of polyunsaturated fatty acids in inflammatory 
diseases
The intervention of cellular functions by bioactive lipids from the diet offers 
an attractive tool to modify or to prevent many pathophysiological processes of 
inflammatory diseases including bronchitis, conjunctivitis, COPD, hepatitis, 
IBD, psoriasis, RA and rhinitis. Dietary n-3 PUFA act via several mechanisms, 
which they primarily conduct by substituting phospholipid pools containing 
arachidonic acid (AA) with EPA and DHA. The enhanced physiological levels of 
EPA and DHA, suppress cyclooxygenase and lipoxygenase and lower synthesis 
of the inflammatory eicosanoids, thromboxane (TXA2) and leukotriene B4 
(LTB4) from 20:4 in platelets and macrophages. Anti-inflammatory effects of 
n-3 PUFA can also be apart from eicosanoid pathway by affecting the expres-
sion pattern of cell surface adhesion molecules which participate in interactions 
between leukocytes and endothelial cells, thereby facilitating the infiltration 
of leukocytes into sites of inflammation [17]. Understanding the influence of 
dietary n-3 PUFA on the modulation of inflammatory complication is hence 
crucial if they need to be exploited as an adjunct therapy in treating many of 
these diseases.
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2.1 Bronchitis
Chronic bronchitis is associated with high morbidity and mortality worldwide 
and has a diverse range of associated factors, including occupational, economic, 
and educational status [18]. The inflammation observed in chronic bronchitis is 
marked by airway eosinophilia, activated T-lymphocytes, rise in the amount of 
TNF-α-positive cells and neutrophils in the bronchial mucosa [1]. The advanced 
stage of the disease also shows similar signs, accompanied by hypertrophy of goblet 
cells, purulent bronchitis, and dilatation (diffuse or localized). The rise in eosino-
phils in bronchitis (caused by allergens, chemicals or drugs, etc.) is characterized by 
asthma and chronic cough and currently treated with anti-inflammatory drugs like 
inhaled corticosteroids. Although a shortcoming of this treatment is that it is most 
helpful only in those respiratory illnesses where eosinophils are elevated, and not in 
other types of bronchitis [19].
Moreover, acute bronchitis which is generally treated with antibiotics has 
several reported undesired side-effects associated with their use- nausea, vomit-
ing or diarrhea, headaches, skin rash, and vaginitis, apart from population-level 
harm from antibiotic resistance [20]. Concerning the chronic form of the disease 
as seen in smokers, etc., rampant use of prophylactic antibiotics does not seem to 
have a considerable effect [21]. In such a scenario, having an effective treatment 
option for bronchitis, that eliminates any adverse effects and can always be effective 
despite widespread and prolonged use, is welcome. Some essential nutrients have 
proven benefits in this regard. A randomized self-controlled study was done using 
n-3 PUFA, vitamin C, and Zn supplementation in asthmatic children showed that 
nutritional intervention could lower the severity of inflammatory diseases. This was 
confirmed by testing the pulmonary function and inflammatory markers present 
in the sputum, where a remarkable improvement was seen in results of those on a 
diet supplemented with n-3 PUFA, vitamin C, and Zn [22]. When n-3 PUFA are 
considered individually, it was established from a study that daily ingestion of 3 g of 
n-3 PUFA for a month by atopic patients, showed reduced bronchial hyperactivity 
and improved responsiveness towards the ultrasonically nebulized distilled water 
[23]. To validate the connection between dietary fats and bronchitis, the patho-
physiology of this condition needs to be addressed. The inflammation is related to 
altered level in membrane fatty acid composition of erythrocytes and an imbalance 
in the precursor of a pro to anti-inflammatory eicosanoid ratio [24]. A comparative 
assessment of the impact of n-3 and n-6 PUFA on respiratory function was done, 
by supplementation of the diet of asthmatic patients with perilla oil (n-3) or corn 
oil (n-6). The study revealed that, leucocytes from the corn oil supplemented group 
generated a greater amount of LTB4 and LTC4 than the perilla oil supplemented 
group, and the anti-inflammatory benefits in the latter were also reflected through 
their improved respiratory function parameters of peak expiratory flow (PEF) in 
the mornings, forced expiratory volume (FEV) and forced vital capacity (FVC) 
[25]. On deeper investigation of the mechanisms of n-3 fatty acid-mediated actions, 
it was found that mice exposed to cigarette smoke to mimic lung injury caused by 
smoke and pulmonary toxicants, on treatment with the resolvin RvD1, exhibited 
potent anti-inflammatory and resolution of inflammation in the lungs when 
supplied after the final smoke exposure. The same study also made use of blood 
monocytes, small airway epithelial cells, and primary human lung fibroblasts, 
which were treated with cytokine IL-1β or an extract of cigarette smoke along 
with RvD1 in in vitro. RvD1 inhibits the release of pro-inflammatory mediators by 
primary human cells in a dose-dependent manner, attenuates neutrophilic lung 
inflammation and release of pro-inflammatory cytokines, along with the upregula-
tion of the anti-inflammatory cytokine IL-10 [26]. Lipoxins and resolvins serve as 
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natural agonists in resolution of pulmonary inflammation. Briefly, lipoxins are ara-
chidonic acid derivatives generated via multistep enzymatic reactions mediated by 
lipoxygenases to produce trihydroxy-tetraene-containing eicosanoids. On the other 
hand, resolvins are endogenous autacoids, derived from EPA and DHA as E-series 
(RvE) and D-series (RvD) resolvins, respectively. The intracellular signaling 
pathways resolvins adopt to bring about their actions, involve NF-Ƙβ and kinases. 
Resolvins can control the NF-Ƙβ signaling pathway, for e.g. RvE1 is an agonist in 
the signal transduction mechanism to inhibit TNF-α induced activation of NF-Ƙβ 
in a concentration-dependent manner. It can also suppress pro-inflammatory 
LTB4-mediated BLT1 signaling by lowering activation of NF-Ƙβ. The mechanism of 
NF-Ƙβ repression is relevant for resolution of inflammation in pulmonary diseases, 
as it induces granulocyte apoptosis. With respect to kinases, the pro-inflammatory 
reactions involved in chronic inflammatory lung diseases, are mainly regulated by 
phosphatidylinositol 3-kinase (PI3-K) and the MAPK family member extracellular 
signal regulated kinase (ERK). In vitro, RvE1 increases phosphorylation of kinases, 
which has a protective effect of controlling apoptotic programs in cells. RvE1 also 
mitigates attenuates inflammatory pain by indirectly inhibiting the ERK signaling 
pathway [27].
2.2 Irritable bowel disease (IBD)
Inflammatory/irritable bowel disease is a broader term used to describe the 
disorders that involve the inflammation of the gastrointestinal tract. Crohn’s disease 
(CD) and ulcerative colitis (UC) are both related to IBD and result from interactions 
between gene, environment, and gut microbiota. Crohn’s disease is characterized by 
chronic inflammation which relapses and remits, ultimately affecting the entire gas-
trointestinal tract, whereas ulcerative colitis inflammation is mostly confined to the 
colon-rectum junction. The pathogenesis of the disease mostly involves predispos-
ing genetic, environmental, and immunologic factors [28, 29]. More than 200 gene 
regions have been identified that confer risk for Crohn’s disease or ulcerative colitis 
in the European population [30]. The currently available drugs to treat IBD work 
by targeting receptors of T-cell activation (e.g., visilizumab, abatacept), prebiotics, 
probiotics targeting the intestinal flora antibiotics, adhesion molecule blockers (e.g., 
MLN-02, alicaforsen, natalizumab), cytokines (e.g., interleukin 10) [31]. Despite the 
advent of new therapeutic agents in recent years, current treatments are modestly 
successful with notable side effects [32]. Also, epidemiologic studies reported that 
increased animal fat/n-6 PUFA intake with the prevalence of both CD [33, 34] and 
UC [35]. Hence it is necessary to understand the role of n-3 PUFA and its metabolites 
in disease prevention of IBD. The potential role of n-3 PUFA in inflammation has 
garnered interest in fatty acid profiling in various metabolic and inflammatory 
diseases. Like other diseases, the inflammatory state in IBD is a result of the eico-
sanoid pathway with elevated levels of LTB4, LTC4, and thromboxanes (A1 and A2) 
in the inflamed intestinal mucosa [4]. Many clinical studies conducted with fish oil 
or EPA supplementation reported the inhibitory effect on inflammatory molecules 
production [36–38]. Animal model studies are in line with results of clinical stud-
ies concluded that n-3 PUFA ameliorated the intestinal inflammation [39–41]. The 
immunomodulatory and anti-inflammatory effects of n-3 PUFA are reported either 
directly [42, 43] or indirectly by the generation of PUFA metabolites containing 
hydroxyl groups i.e. resolvins, hydroxy fatty acids etc. [44]. Although there is a rea-
sonable amount of data available on anti-inflammatory effect of n-3 PUFA, limited 
reports available in their use on IBD patients; hence deeper research in the aspects 
of dose, and mechanistic understanding is needed to replace or enhance the effect of 
currently available drugs along with nutritional intervention.
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2.3 Psoriasis
Psoriasis is an inflammatory skin disease, affecting about 2% of the general 
population, characterized by hyperproliferation and poor differentiation of kerati-
nocytes, increased vascularization of the skin, leukocyte infiltration and fibroblast 
activation [45]. It is a skin disease considered to be resulting from T-cell-mediated 
inflammation, wherein the inflammatory reaction is controlled by diet, lifestyle, 
and environmental cues such as infections and stress. Although the etiology 
remains unknown, accumulating evidence indicates that cytokines, mainly tumor 
necrosis factor α (TNF-α), IL-17 and IL-23, play essential roles in the development 
[6]. In the psoriatic lesions, inflammatory dermal dendritic cells (DCs) produce 
IL-23 that enhances the production of T cytotoxic 17 cells (Tc17) or IL-17 from T 
helper 17 cells (Th17) in the skin, leading to epithelial hyperplasia and inflamma-
tory cell infiltration [46]. A documented and conclusive cure for psoriasis does not 
exist, some of the commonly used treatments to reduce the severity of disease and 
lessen the impact are phototherapy, topical and systemic therapies in moderate-to-
severe psoriasis and drugs are corticosteroids, methotrexate, tar, cyclosporine, and 
emollients. Nevertheless, almost all the mentioned treatments are accompanied by 
major adverse effects [47]. Among nutritional components regulating the patho-
physiology of psoriasis, PUFAs proved to be promising in the treatment of many 
skin diseases as safe, including psoriasis [48]. Calorie restriction or weight loss may 
also influence the severity of the disease. However randomized control trial study 
conducted by Guida et al. concluded that calorie restriction (20 kcal/kg/day) along 
with n-3 PUFA (2.6 g/day) enriched diet improved the clinical response of immune-
modulating drugs in obese psoriatic patients [49]. Many clinical studies have dem-
onstrated that the administration of fish oil or n-3 PUFA ethyl esters in psoriatic 
animal model/patients ameliorated the degree of skin inflammation [ 44–48, 50]. 
However, the reports on the exact mechanism are limited. A recent study conducted 
by Sawada et al. using metabolite produced by n-3 PUFA such as resolvinE1 (RvE1) 
in imiquimod (IMQ )-induced murine psoriasis mouse model concluded that RvE1 
remarkably suppressed the epidermal hyperplasia and inflammatory cell infiltra-
tion in the psoriatic skin. These suppressive effects are due to the antagonistic effect 
of RvE1 on BLT1 production, a receptor of LTB4 and decrease in mRNA expression 
of cytokines (IL-17 and IL-23) indicating the novel mechanism of psoriatic patho-
genesis and potential of RvE1 as an adjuvant in the psoriatic therapy [51].
2.4 Chronic obstructive pulmonary disease (COPD)
COPD is a chronic inflammatory lung disease triggered by exposure to toxic 
particles and gases, especially, cigarette smoke. Some of the predominant charac-
teristics of COPD include parenchymal destruction, poorly reversible, persistent 
airflow limitation, and chronic bronchitis. A COPD patient shows some visible 
symptoms like cough, chest tightness dyspnoea, excess sputum production, and 
wheezing [52]. COPD is coordinated by a complex network of inflammatory 
mediators, such as inflammatory enzymes, lipid mediators (eicosanoids, namely 
prostanoids and leukotrienes, LTs), interleukins (ILs), and adhesion molecules, 
which may moderate airway inflammation through chemotactic and autocrine or 
paracrine effects [3]. Eicosanoids are produced by cells resident in the lung and 
airways, such as fibroblasts, epithelial cells, myofibroblasts, and smooth muscle 
cells, also by inflammatory cells that have migrated from the circulation to the 
airways, such as macrophages, mast cells, neutrophils, platelets, eosinophils, and 
T-lymphocytes [53]. Activated macrophages release cytokines such as IL-8, IL-6, 
IL-10, TNF-α, and LTB4, which can attract and activate various inflammatory cells. 
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Smooth muscle cells, fibroblasts, and myofibroblasts play a key regulatory role in 
airway remodeling by generating different structural components, such as collagen 
and proteoglycans [54]. Although the mediators involved in structural remodel-
ing of the bronchial wall remains unknown, chemokines, cytokines, and growth 
factors are thought to have a crucial role. Observational clinical studies suggest 
that n-3 PUFA levels in COPD are inversely related to systemic inflammation and 
directly related to clinical outcomes [55–57]. Interventional studies using n-3 
PUFAs alone in COPD do not exist; however, many trials are currently underway, 
which may generate valuable data in the coming years [58–60]. An animal study in 
pneumonia model of mice, revealed RvE1 metabolite of n-3 PUFA decreased levels 
of several pro-inflammatory chemokines and cytokines in the lung, and improved 
survival [61]. However, currently, there is a paucity of data regarding the potential 
of n-3 PUFAs to be used therapeutically in COPD. Recent studies, conducted using 
omega-3 PUFAs in COPD has used nutrient combinations, in a manner that the 
exact effects of omega-3 PUFAs cannot be elucidated.
2.5 Rheumatoid arthritis
Rheumatoid arthritis (RA) is a low grade chronic inflammatory autoimmune 
disease affecting the joints and bones. RA and systemic lupus erythematosus (SLE) 
are multisystem autoimmune diseases featuring the production of a variety of auto-
antibodies, and resulting in higher immune-mediated inflammation. Prevalence 
of RA is known to affect 17.6 million people worldwide [7] with the huge economic 
burden to mankind. Pathogenesis of RA in early phase focused on auto-antibodies 
and immune complexes [62], however, the nature of T-cell mediated antigen-specific 
responses, T-cell-independent cytokine species, and aggressive tumor-like behavior 
of rheumatoid synovium have also been reported. Immune complex theory strongly 
suggests increased neutrophils accumulation in synovial fluid results in engulfment 
of immune complex and release proteolytic enzymes [62]. A better understanding 
of the intracellular targets that regulate cytokines in RA can potentially lead to new 
therapeutic interventions. For instance, studies reported activation of NF-κB in 
the synovium of RA patients [63] and mitogen-activated protein (MAP) kinases 
are identified as vital regulators of cytokine and metalloproteinase production. 
The mechanistic approach to currently available drugs is partially understood and 
mostly targeting the eicosanoid pathway, and reports are scarce about gene targets 
on CD28, AP-1, and MAP kinases. Investigators have examined the effect of dietary 
fatty acid supplementation in different autoimmune diseases, and the effects of 
both n-6 and n-3 PUFA on RA have been reported [64]. Resolvins derived from EPA 
and DHA are anti-inflammatory and resolve inflammation, serving as important 
mediators in regulating various homeostatic functions, including gastric mucosal 
integrity. Kremer and co-workers reported that a dose of 90 mg/kg/day EPA/DHA 
(3:2 ratio) showed a shorter period to respond than 45 mg/kg/day [65]. Clinical 
studies have ambiguity in results, few observed reductions in both tender joints by 
36% and swollen joint to 38% in patients, whereas the placebo group showed no 
improvement in these parameters [66]. Fish oil supplementation in women patients 
showing a decrease in the production of serum nuclear factor-kappa B (Nf-kB) 
ligand/osteoprotegerin ratio [67]. Cell culture-based investigations have reported 
that EPA and DHA prevent the proliferation of human T cells and their generation 
of IL-2 [68]. Animal studies also reported a beneficial effect of marine n-3 PUFA in 
RA [69, 70]. Finally, supplementation with dietary n-3 PUFA and its ability to inhibit 
TNF-α and IL-1b synthesis is rational. Considering the emphasis on recommenda-
tions to increase dietary n-3 PUFA intake for health benefits, the possible therapeutic 
potential of fish oil/n-3 PUFA on autoimmune diseases need to be clearly defined.
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2.6 Conjunctivitis
Conjunctivitis is an ocular inflammatory condition of the membrane lining the 
eyelid, which provides a shelter to the open surface of the sclera [71]. It is said to be 
the most common cause of “red eye,” and the infection, either acute or chronic can 
originate from three different sources, based on which it is commonly classified: viral, 
allergic, and bacterial conjunctivitis. The type of conjunctivitis may be determined by 
a diagnostic investigation which takes into account, the patient’s age, time of the year, 
and physical examination findings [72]. Identification of the pathogen which elicits 
the inflammatory response is necessary to decide on the required treatment module, 
since some bacterial conjunctivitis forms are self-limiting, while those caused by 
Chlamydia trachomatis or Neisseria gonorrhoeae demand aggressive antibiotic therapy, 
and primarily good eyelid hygiene [71]. The visual symptoms of inflammation at the 
ocular surface, include, lid and conjunctival edema–redness, tearing, extreme itching, 
and photophobia during the acute phase cause immense discomfort, thereby necessi-
tating treatment [73]. Effective pharmacological cure comprises antihistamines, mast 
cell stabilizers, and non-steroidal anti-inflammatory drugs [74]. The excess wateri-
ness experienced during conjunctivitis and also early dry eye disease is because of 
enhanced goblet cell mucin secretion into tears, which otherwise produce a regulated 
amount of mucins only to protect the eye. This phenomenon is due to the action of 
inflammatory mediators, cysteinyl leukotrienes LTB4, LTC4, LTD4, and LTE4, and 
prostaglandin PGD2, which stimulate conjunctival goblet cell mucous secretion. 
Thus, mitigation of this LTD4 effect can aid in reducing mucin secretion, and this has 
been achieved previously by the action of Resolvins D1 (RvD1) and E1 (RvE1) [2]. 
The finding of Dartt and co-workers [2] indicates that lipids including fatty acids or 
lipid mediators play a role in suppression of systemic inflammation as well as local, 
such as in the case of inflammatory conjunctivitis. The connection between the qual-
ity of fat consumed and conjunctivitis was drawn from the results of a Japanese study, 
which states that meat intake is directly proportional to the prevalence of rhinocon-
junctivitis in young adult Japanese women, while no correlation was seen between 
fish intake and rhinoconjunctivitis [75]. Though, there are not many reports from 
similar controlled clinical trials that specifically correlate meat intake with incidence 
of conjunctivitis, to ascertain such claims. The study does raise questions on the 
role of fats present in meat that possibly trigger the pathways in inflammation. The 
true potential of n-3 PUFA as an anti-inflammatory in managing conjunctivitis was 
elucidated through other detailed investigations of their actions and mechanisms at 
molecular levels. A primary mode of action is that of the resolvin mediated responses, 
as mentioned earlier. The process of resolution of inflammation is an active process 
facilitated by pro-resolution lipid mediators. Not only D-series resolvins RvD1, which 
are produced in the cornea but also aspirin-triggered RvD1 (ATRvD1) have exhibited 
regulation of inflammatory responses to histamine in allergic conjunctivitis. The 
effect is implemented by a cross-talk between two types of G protein-coupled recep-
tors (GPCRs). When RvD1 interacts with its receptor GPR32, it prevents the hista-
mine-stimulated H1 receptor-mediated rise in intracellular Ca2+, thereby blocking H1 
receptor-mediated responses. Consequentially, this activates extracellularly regu-
lated–protein kinase (ERK) 1/2 [76]. In addition to resolvins, another class of lipid 
mediators that can mimic these anti-inflammatory actions in conjunctivitis includes 
lipoxins, especially, lipoxin A4 that has benefits similar to that of ATRvDI and can 
activate ALX/FPR2 receptor to regulate conjunctival goblet cell secretion, which is 
particularly useful in maintaining ocular surface homeostasis, and managing the dry 
eye syndrome [77]. Another evidence of polyunsaturated fats aiding in the treatment 
of conjunctivitis emerged on evaluating the impact of the feeding of omega-3 and 
omega-6 PUFA on human leukocyte antigen-DR (HLA-DR) marker of conjunctival 
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inflammation in dry eye patients; it was observed that increased intake of both these 
fatty acids suppressed the expression of HLA-DR [78]. With this, it is evident that 
dietary supplementation of n-3 PUFA has a modulatory effect on conjunctivitis. Their 
efficacy has been tested in mammals such as dogs affected with keratoconjunctivitis 
sicca, where EPA + DHA + antioxidants in defined proportion was used as an adju-
vant [79]. Furthermore, their use of topical treatment has also been suggested in the 
literature. Based on data from animal preliminary human studies, protectins (NPD1) 
and DHA turn out to be a safe, effective treatment for dry eye through a topical 
application [80] . Ultimately, investigators have also proposed formulations for active 
use in therapy, one such patented formulation by Aleo et al. [81], clearly provided the 
n-3 and n-6 PUFA proportion for creating an ophthalmic composition suitable for 
ocular inflammation.
2.7 Hepatitis
Hepatitis is the inflammation of the liver with symptoms that generally include 
right upper abdominal pain, headache, fatigue and malaise, myalgia, altered sense 
of smell or taste, nausea and vomiting, coryza, photophobia, diarrhea (may have 
pale stools and dark urine) [5]. Hepatitis treatment can be managed better without 
any inconveniences, with the help of dietary interventions, which not only limit the 
progression of hepatitis but can also be used as a novel therapy. Considering the abun-
dant evidence of n-3 PUFA and their anti-inflammatory effect in most liver maladies, 
including fatty liver disease, cirrhosis, and acute liver failure, their role in immune-
mediated liver diseases is not fully exploited. Fatty acids belonging to the n-3 family 
have been shown to suppress hepatitis via an autophagy-dependent mechanism and are 
particularly helpful for therapy in autoimmune hepatitis [82]. In this regard, the n-3 
PUFA mediators resolvin D1 and E1 can be particularly useful, as they inhibit concana-
valin A-induced liver injury and restricting the progression of hepatitis to liver cancer 
in mice through suppression of NF-kβ/AP-1 activity [83]. The actions of n-3 PUFA 
were evaluated in a macrophage-dependent acute D-galactosamine/lipopolysaccharide 
(D-GalN/LPS) hepatitis model in the transgenic fat-1 mice. The findings clearly stated 
that the n-3 PUFA supplementation dampened the severity of the inflammatory liver 
injury and histological liver damage in fat-1 mice. The balance in n-6/n-3 PUFA ratio 
was improved, and levels of serum alanine aminotransferase and TNF-α and IL-1β 
cytokine production were lowered. The effect was confirmed through the lowered 
hepatic gene expression of all the pro-inflammatory cytokines, thus proving their 
anti-inflammatory benefits in the framework of liver inflammation [84]. The most 
striking feature of n-3 PUFA therapy in HCV was discovered when the efficacy of EPA 
was evaluated against ribavirin (RBV) associated hemolytic anemia. When EPA was 
supplemented with the standard combination therapy of peginterferon (PEG-IFN) 
and ribavirin (RBV), patients receiving EPA, required reduced RBV doses compared 
to the non-EPA group, and also showed decreased RBV-induced hemolysis, although 
rates of virological response are yet to be elucidated [85]. Therefore, it is encouraging 
that EPA can lower dependency on drugs in even such morbid disorders. Some of the 
other adverse effects of RBV treatment which have been effectively countered by n-3 
PUFA include lowering of the impairment of the filterability of erythrocytes of chronic 
HCV patients in whom erythrocyte filterability was caused due to oxidative membrane 
damage induced by RBV which led to hemolytic anemia [86]. This finding further 
ensures the maintenance of the lymphocyte levels and improvement in hemoglobin 
levels in the patients of PEG-IFN and RBV treatment [87]. Thus, n-3 PUFA and their 
mediators can be recommended for concurrent administration with the recommended 
standard interferon and antibiotic therapy, to facilitate recovery, ameliorate adverse 
effects, and prevent mortalities in chronic cases.
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2.8 Rhinitis
Allergic rhinitis (AR) is a highly prevalent heterogeneous disorder, caused by 
pollens, molds, dust mites, and animal dander, but often goes undiagnosed as a 
condition of rhinitis. The symptoms of AR, which include sneezing, itching, nasal 
congestion, and rhinorrhea are mostly IgE mediated and triggered through muco-
sal infiltration and action on eosinophils, plasma cells, and mast cells, [7]. Some 
other discomforts experienced by the patients in chronic rhinitis include sinusitis, 
eustachian-tube dysfunction, sleep disturbances, and forces the patient to breathe 
through the mouth. AR may not appear as a serious ailment but is clinically relevant 
as it triggers numerous complications, is a potential risk factor for asthma, deterio-
rates the quality of life and efficiency at work. The range of pharmaceutical options 
available to manage a rhinitis episode includes intranasal corticosteroids, which are 
effective and safe. The most common drug type is that of first-generation antihis-
tamines, but they are well-known to cause sedation, psychomotor retardation, and 
decreased academic performance. AR is tackled most effectively from its natural 
history, using immunotherapy by targeting allergens singly [88]. Various dietary 
factors have been associated with allergic rhinitis, such as dietary antioxidants in 
vegetables may reduce wheezing symptoms, but fats such as butter and margarine 
tend to aggravate the symptoms [89]. The exact mechanism by which saturated fats 
alter airway inflammation has neither been fully understood nor has it received 
much attention. Yet, reports suggest that accumulation of saturated fatty acids is 
associated with changes in levels of serum cholesterol and arachidonic acid content 
in the cell membranes, which together modify the lymphocyte function. These 
observations and other epidemiological data led to the conclusion that saturated 
fats aggravate rhinitis, asthma and related conditions [90]. Since saturated fats were 
implicated in worsening rhinitis, the effect of unsaturated fats on allergic sensitiza-
tion and allergic rhinitis was also investigated by many researchers. It was found that 
the presence of unsaturated fatty acids in membranes of red blood cells (RBC) in 
the form of EPA and the diet as ALA, lower sensitivity and incidence of rhinitis [8, 
91]. Fish consumption during pregnancy as well as childhood was associated with 
a lowered risk of any respiratory illnesses—allergic rhinitis, wheezing or asthma in 
childhood and later, and long chain n-3 PUFA supplementation was also not related 
to the risk of postpartum hemorrhages in mothers as well [92, 93]. An insight into 
the mechanism by which this effect is achieved suggests that n-3 PUFA supplementa-
tion during pregnancy boosts levels of placental DHA and specialized pro-resolving 
lipid mediators (SPM) precursors without aggravating inflammatory gene expres-
sion [94]. Also, adjunctive supplementation of fish quickens the effects of routine 
pharmacotherapy in AR subjects by lowering AR related symptoms and serum levels 
of Ig E, which is crucial since IL-5 and Ig E are found in higher concentrations in 
nasal secretion and sputum of AR patients [95]. With such abundant information 
pointing towards the preventive and prophylactic effects of polyunsaturated fatty 
acids on the rhinitis, the dietary incorporation of n-3 PUFA, as well as their use as 
adjuvant therapy for lowering the incidence and severity of a rhinitis episode, can 
be strongly recommended. These fatty acids have also demonstrated a potential to 
slow down the progression of chronic rhinitis, thereby improving quality of life and 
productivity at work.
3. Summary and conclusion
Taken together, findings from in-vitro and in-vivo studies of inflammatory 
diseases suggest that n-3 PUFA could be potential therapeutic molecules to combat 
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inflammatory diseases as described in this chapter. The results from mechanistic 
studies reveal the effects of LC-PUFAs (n-6 and n-3) on human health are highly 
favorable. However, the relation between the two families of LC-PUFAs on the 
mechanisms of action needs to be further understood as the presence of these 
two fatty acids in the diet play a significant effect on the metabolism of other. The 
inflammatory mechanism involved in the pathogenesis provides novel candidature 
targets for cost-effective pharmacological and nutraceutical drugs. Despite a better 
understanding of the beneficial effects of LC-PUFAs, there is a lack of data on 
attempts to replace or supplement with currently available drugs. Investigating 
the synergistic potential of various food bioactive molecules with existing clini-
cally proven drugs could be the most effective therapy to ameliorate many of these 
inflammatory diseases.
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